All In Biotech

Free tool

FAERS Monitor: Sirturo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204384 or its brand name (Sirturo, Bedaquiline Fumarate). Reports on generic versions are filed under their own applications.

Reports

1,441

Serious

1,379

96% of reports

Hospitalization

479

Death reported

341

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • electrocardiogram qt prolonged223
  • off label use174
  • hepatotoxicity149
  • anaemia146
  • neuropathy peripheral109
  • nausea93
  • death73
  • intentional product use issue72
  • vomiting72
  • decreased appetite46
  • dyspnoea46
  • dizziness44
  • hypokalaemia40
  • asthenia34
  • headache34

Reports by year received

View as table
YearReports
20141
201521
201632
201774
2018199
2019266
2020155
202177
2022193
2023145
2024119
2025102
202657

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,718 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatotoxicitySignal14998.384.414,177
electrocardiogram qt prolongedSignal22391.180.719,684
neuropathy peripheralSignal10916.714.01,603
hypokalaemiaSignal4012.79.3419
intentional product use issueSignal7212.09.6718
anaemiaSignal14611.29.61,355
off label useSignal1742.92.5224
decreased appetiteSignal462.92.256
vomitingSignal722.21.849
nausea931.71.428
asthenia341.30.92
dizziness441.31.03
death731.21.03
dyspnoea461.20.91
headache340.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.